Last reviewed · How we verify
Fosfomycin-Trometamol
Fosfomycin-Trometamol is a Small molecule drug developed by Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH. It is currently FDA-approved. Also known as: Monuril.
At a glance
| Generic name | Fosfomycin-Trometamol |
|---|---|
| Also known as | Monuril |
| Sponsor | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- FOsfomycin for Male Urinary Tract Infection (PHASE3)
- Preoperative Prophylactic Fosfomycin Trometamol Versus 5-day Levofloxacin in Prevention of Postpercutaneous Nephrolithotomy Infectious Complications and Sepsis. (NA)
- Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder (PHASE4)
- Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women. (PHASE4)
- Efficacy of Collagen, Propolis Plus Quercetin (Proqutin®), Bacillus Coagulans, Hyaluronic Acid and Chondroitin Sulphate and D-Mannose to Avoid Symptoms and Prevents Recurrence in Women With Recurrent Urinary Tract Infections (PHASE4)
- Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections (PHASE3)
- Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection (PHASE3)
- Efficacy and Safety of Uronext® in Women With Cystitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fosfomycin-Trometamol CI brief — competitive landscape report
- Fosfomycin-Trometamol updates RSS · CI watch RSS
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH portfolio CI
Frequently asked questions about Fosfomycin-Trometamol
What is Fosfomycin-Trometamol?
Fosfomycin-Trometamol is a Small molecule drug developed by Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH.
Who makes Fosfomycin-Trometamol?
Fosfomycin-Trometamol is developed and marketed by Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH (see full Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH pipeline at /company/institut-fuer-anwendungsorientierte-forschung-und-klinische-studien-gmbh).
Is Fosfomycin-Trometamol also known as anything else?
Fosfomycin-Trometamol is also known as Monuril.
What development phase is Fosfomycin-Trometamol in?
Fosfomycin-Trometamol is FDA-approved (marketed).
Related
- Manufacturer: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH — full pipeline
- Also known as: Monuril
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing